Hundreds of kidney injury lawsuits filed against the manufacturers of Nexium, Prilosec, PrevAcid, Protonix and Dexilant continue to move forward in the federal multidistrict litigation now underway in the U.S. District Court, District of New Jersey.
According to a Case Management Order dated April 26th, the litigation convened its most recent Status Conference on April 10th. Among other things, the Court denied the Plaintiffs’ proposed order regarding the filing of bundled complaints. The parties have been directed to meet and confer on a tolling agreement and provide the Court with an update at the next conference.
The Court also directed the parties to submit a Case Management Order governing Science Day no later than May 1st.
Plaintiffs also reported that they have reached agreement on a Defense Fact Sheet (“DFS”) with the Pfizer/Wyeth Defendants. The remaining Defendants are to meet and confer with Plaintiffs on a DFS and report back to the Court at the next status conference.
Millions of Americans use prescription or over-the-counter proton pump inhibitors to relieve symptoms associated with GERD and other acid-related stomach disorders. While few people give much thought to their potential side effects, recent studies have linked extended use to a range of serious complications, including bone fractures, certain bacterial infections, heart attacks, dementia, vitamin B deficiency, and low magnesium.
A growing number of studies have also suggested that long-term proton pump inhibitor use may increase a patient’s risk for severe kidney problems, including:
More than 2,300 proton pump inhibitor lawsuits are currently pending in the District of New Jersey, all of which were filed on behalf of individuals who developed kidney failure, chronic kidney disease and other life-threatening renal complication allegedly related to their long-term use of Nexium and similar heart burn drugs.
The U.S. Judicial Panel on Multidistrict Litigation centralized all federally-filed proton pump inhibitor lawsuits that put forth similar allegations concerning kidney damage last August, transferring just 161 cases to the District of New Jersey.
Plaintiffs with Nexium lawsuits and other proton pump inhibitor claims pending in the proceeding charge that the drugs’ manufacturers have long been aware of evidence linking their products to serious kidney injuries, but failed to warn doctors and patients of these risks. They further allege that they could have avoided these kidney side effects had they received adequate warnings from the Defendants.